Purpose. Solute carrier OCTN1 (SLC22A4) is an orphan transporter, the physiologically important substrate of which is still unidentified. The aim of the present study was to examine physiological roles of OCTN1. Methods. We first constructed octn1 gene knockout (octn1 −/− ) mice. Metabolome analysis was then performed to identify substrates in vivo. The possible association of the substrate identified with diseased conditions was further examined.
INTRODUCTION
Carnitine/organic cation transporter OCTN1 (SLC22A4) was originally identified in our laboratory as a multispecific transporter which preferentially recognizes organic cations and, to a lesser extent, carnitine, which is essential for β-oxidation of fatty acids in mitochondria, as substrates (1, 2) . In addition, Gründemann et al. have previously reported that ergothioneine is also a good substrate for OCTN1 in vitro, by utilizing cell biological and metabolomics approaches (3) . Despite the previous identification of various substrates for OCTN1 in in vitro experimental systems, biologically important substrates for OCTN1 in vivo have not yet been clarified. OCTN2 (SLC22A5) is another member of the OCTN family and is much more carnitine-selective (4, 5) . A physiologically pivotal role of OCTN2 in reabsorption of carnitine in proximal tubules has already been identified: a missense mutation in the octn2 gene of a naturally occurring mutant or juvenile visceral steatosis (jvs) mouse or in the OCTN2 gene of humans leads to systemic carnitine deficiency (6) .
Both OCTN1 and OCTN2 genes are located on cytokine cluster region in chromosome 5q, which is possibly associated Electronic supplementary material The online version of this article (doi:10.1007/s11095-010-0076-z) contains supplementary material, which is available to authorized users.
with various inflammatory diseases. OCTN1 gene was actually reported to be associated with rheumatoid arthritis (7), whereas both OCTN1 and OCTN2 genes have been proposed to contribute directly to susceptibility to Crohn's disease (CD) in European people (8) . However, the reported mutations in these genes (C1672T and G-207C, respectively) were absent or not associated with CD in Japanese patients (9) , supporting the existence of ethnic difference in genetic variants causative of CD. In addition, the variants in these two genes appeared not to be causative even in European populations according to a recent analysis of more than a thousand pairs (10) . Thus, the precise locus directly linked to CD susceptibility has not yet been elucidated, probably because of the limitations of a purely genetic approach.
Considering the association of the OCTN2 gene with CD (8) , experimental animals with mutation of the octn2 gene would be useful tools to explore the pathogenesis of CD. This idea is supported by recent findings of spontaneous development of intestinal atrophy and inflammation in jvs mice, demonstrating an obligatory role of OCTN2 in the maintenance of normal intestinal morphology (11) . On the other hand, little is known about the physiological role of OCTN1, mainly because appropriate gene-deficient animals are not available. In the present study, we first developed octn1 gene knockout (octn1 −/− ) mice with the aim of employing them to examine the biological roles and possible association of OCTN1 with any diseased conditions. The metabolome analysis using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) of blood and several organs indicated complete deficiency in octn1 −/− mice of a naturally occurring potent antioxidant ergothioneine, which was found to be highly accumulated in small intestine after oral administration. The greater susceptibility to intestinal inflammation in the octn1 −/− mice and the lower blood levels of ergothioneine in Japanese CD patients may suggest possible linkage between this antioxidant and small intestinal diseases.
MATERIALS AND METHODS

Construction of octn1
The octn1 −/− mice were generated according to the method previously reported (12) . PCR was first performed with genomic DNA derived from E14-1 ES cells in order to isolate the homologous regions of octn1 gene. The targeting vector consisted of 8.5 kb of the 3′ homologous region, 1.2 kb of the 5′ homologous region of octn1gene, the neomycin resistance (Neo r ) gene cassette driven under the phosphoglycerate kinase I promoter (13) and subunit A of the diphtheria toxin (DT-A) gene cassette driven under the MC1 promoter (14) . With this targeting vector, exon 1 (including the start codon) should be deleted (Supplementary Figure 1) . The vector construction and purification were performed by means of E. coli DH5α. The linearized targeting vector (20 μg) was then electroporated into ES cells, and recombinants were selected with 180 mg/mL of active form G418 (Gibco/BRL) for 7-10 days. More than 500 clones of embryotic stem cells were screened by genomic PCR. Three of them were subjected to Southern blot analysis, and two clones (1B5 and 3B3) were selected to generate octn1 −/− mice (Supplementary Figure 1B) . Chimeric mice were generated by the aggregation method. Chimeras were mated with C57BL/6J females, and homozygous mutant mice were generated by crossing of the heterozygotes. Mice were given normal commercial diet, PicoLab Rodent Diet 20 (PMI Nutrition International, St. Louis, MO), and water ad libitum. They were kept in an environmentally controlled clean room at the Institute of Experimental Animals, Advanced Science Research Center, Kanazawa University.
Genotypes in mice were determined by a PCR method using genomic DNA prepared from mouse ear. The forward primer (5′-catttcagaagtaaagaaaccctgcgag-3′) was localized outside the targeting vector, whereas the reverse primer outside exon 1 (5′-gaaagtgggggcctcgacatag-3′) or that at the end of the PGKneobpA cassette (5′-ctatggcttctgaggcggaaagaacc-3′) was used to detect wild-type and mutant locus, respectively (Supplementary Figure 1A ). PCR was carried out for 40 cycles at 94°C for 30 sec, 64°C for 30 sec and 72°C for 2.5 min using a Platinum PCR SuperMix (Invitrogen). Deletion of the octn1 gene and loss of expression of the gene product in kidney membrane fraction of octn1 −/− mice were confirmed (Supplementary Figure 1C  and D) . All the animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals in Kanazawa University.
Southern Blot Analysis
Southern blot was performed as previously described (15) . Genomic DNA prepared from mouse liver was digested with Xba I, electrophoresed through a 0.8% agarose gel, and transferred to Hybond-N+ (GE Healthcare). Hybridization was carried out using 32 P-labeled DNA probes made by Megaprime DNA Labelling System (GE Healthcare).
Western Blot Analysis
Western blot was performed as previously described (15) . The membrane fraction prepared from mouse kidneys was separated by 12% SDS-polyacrylamide gel, followed by the transfer of the proteins to polyvinylidene difluoride membrane (Immobilon, Millipore). The membrane was incubated with polyclonal anti-peptide antibodies against the carboxyl terminus of mouse OCTN1 for 2 hr, and then incubated with secondary antibody (donkey anti-rabbit IgG, horseradish peroxidase-linked whole antibody, GE Healthcare). The proteins were detected by means of the enhanced chemiluminescence detection method using the ECL Plus Western-blotting detection system (GE Healthcare).
Differential Metabolomics
The wild-type and octn1 −/− mice were fasted overnight with free access to water and then anesthetized with pentobarbital (60 mg/kg), followed by collection of urine from a bladder cannula for 30 min. Blood and tissues were then obtained, and metabolites were extracted and subjected to CE-TOFMS analysis as described previously for detection of cationic and anionic metabolites, and nucleotides (16, 17) .
Analysis of Ergothioneine by Means of HPLC
All the tissue samples were weighed, and portions were homogenized with two volumes of distilled water. The homogenized tissues, urine, plasma and blood were deproteinized with acetonitrile and subjected to HPLC after centrifugation. The HPLC system incorporated a model PU-2080 pump and a model UV-2075 monitor (Jasco) with a 250× 4.6 mm i.d. Atlantis HILIC silica column (Waters). The mobile phase was 0.1 M ammonium formate and methanol at a ratio of 95:5. The flow rate was 1 mL/min. The wavelength for UV detection was 268 nm. Cephaloridine was used as the internal standard.
Pharmacokinetic Study in Mice
Male mice (8 weeks old) were fasted overnight with access to water and were anesthetized by intraperitoneal injection of pentobarbital. After oral administration of [ 3 H]ergothioneine (Moravek Biochemicals) at 330 μg/kg, each mouse was kept in a metabolic cage during the experiment. Blood samples were collected from the tail vein using heparinized capillary tubes at 1 h, and 1, 2, 3, 5, 7, 10 and 14 days under anesthesia. Urine samples were collected using a metabolic cage. Plasma, blood and urine samples were mixed with scintillation fluid (Clearsol, Nakarai Tesque) for quantitation. At 14 days, tissues were excised, rinsed with ice-cold saline, blotted to dryness and weighed. Tissue samples (0.05-0.2 g) were dissolved in 1 mL of Soluene-350 (Packard), mixed with scintillation fluid, and neutralized with 5 M HCl, followed by determination of the associated radioactivity.
Intestinal Ischemia and Reperfusion Injury
Male mice (10-12 weeks old) were fasted for 18-20 hr with free access to water and were anesthetized by intraperitoneal injection of pentobarbital. A midline laparotomy was performed, and the superior mesenteric artery was occluded with an arterial microclamp. Intestinal ischemia was confirmed by pulselessness of the mesentery and paleness of the intestine. After 60 min, the clamp was removed, and the mice were sutured. Intestinal tissue sections were deparaffinized, rehydrated and stained with hematoxylin and eosin. Differences in survival of wild-type and octn1 −/− mice were determined by means of the log-rank test. Statistical analysis was performed using GraphPad Prism version 4.0 (GraphPad Software San Diego).
Transport Studies in Renal Brush Border Membrane Vesicles
The brush border membrane vesicles were prepared essentially as previously described with a little modification (18) . Transport studies were performed by rapid filtration technique at 25°C.
Blood Sampling in Humans
Unrelated Japanese adult patients with CD (n=25, 14∼47 years old, 18 male and 7 female) and ulcerative colitis (UC, n=16, 18∼70 years old, 8 male and 8 female) were enrolled from Kanazawa University Hospital. Unrelated Japanese adult healthy volunteers (n=31, 21∼36 years old, 22 male and 9 female) were recruited from Kanazawa University Hospital and the Faculty of Pharmaceutical Sciences, Kanazawa University. Informed consent was obtained from all the subjects. The study protocol was approved by the ethics committee of Kanazawa University Graduate School of Medical Science (Kanazawa, Japan), and the study was carried out in accordance with the Declaration of Helsinki. Blood samples (5∼10 mL) were drawn from the brachial vein of the subjects. Statistical analysis was performed by means of one-way ANOVA followed by Dannett's multiple comparison test.
Genotyping in Human Samples
Blood samples were obtained from Japanese adult patients (N=256) with CD in Kanazawa University Hospital, Kyushu University Hospital and Fukuoka University Hospital. DNA was isolated using the QIAamp DNA Blood Mini Kit (QIAGEN, Tokyo, Japan). The DNA sequence was analyzed by sequence-specific PCR using the primers shown in Supplementary Table I . The genomic sequencing was performed for all the exons of OCTN1 and OCTN2. Since several introns can also be sequenced by the primers used in the present study, allelic frequency of such introns was also analyzed. The SNP at the 5′-UTR region of OCTN2 (G-207C) was previously reported to be associated with CD in Caucasians (8) and was also analyzed in the present study. Exon 1 of OCTN1, and the 5′-UTR and exon 1 of OCTN2 were amplified in a total volume of 25 μl, with 5 ng of genomic DNA, 10 μM of each amplification primer, 2.5 mM of each dNTP, 2 × GC rich buffer I and 1.25 units of LA Taq DNA polymerase (TaKaRa). The PCR reaction was initial denaturation at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing for 30 s and extension at 72°C, and a final extension at 72°C for 7 min. The annealing temperature and extension time are shown in Supplementary Table I. Other regions were amplified in a total volume of 25 μL, with 5 ng of genomic DNA, 10 μM of each amplification primer, 2.5 mM of each dNTP, 5 × Expand High Fidelity Reaction buffer without 7.5 mM MgCl 2 and 2.5 units of Expand High Fidelity Enzyme Blend (Roche). All samples were sequenced using a BigDye Terminator v3.1 Cycle Sequencing Kit (ABI PRISM). The sequence reaction was initiated by denaturation at 96°C for 2 min, followed by 35 cycles of 96°C for 10 s, 50°C for 5 sec and 60°C for 1 min, and a final extension at 60°C for 7 min. All samples were confirmed by sequencing on an ABI 310 DNA sequencer (Applied Biosystems). The study protocol was approved by the ethical committees of Kanazawa University, Kyushu University and Fukuoka University.
RESULTS
Metabolome Analysis Revealed Complete Loss of Ergothioneine in the octn1
−/− Mice Targeted disruption of the octn1 gene was first performed by homologous recombination. The octn1 −/− mice thus obtained were born at the expected Mendelian ratio (Supplementary Figure 1E) , developed normally and did not display any gross phenotypic abnormalities. Most of the biochemical parameters of sera examined exhibited minimal difference between wild-type and octn1 −/− mice, and some parameters exhibited minor, but significant difference only in female mice (Supplementary Table II) . To identify any possible phenotypes observed in the octn1 −/− mice, we then applied a metabolome differential display method based on capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) (16) to compare the metabolites of wild-type and octn1 −/− mice. Only ergothioneine was found to be completely absent in erythrocytes of octn1 −/− mice (Supplementary Figure 2) . In this analysis, we quantitatively measured 112 metabolites by means of CE-TOFMS (16, 17) and confirmed the loss of ergothioneine in heart, liver, small intestine, kidney and erythrocytes of octn1 −/− mice (Fig. 1) . Ergothioneine level was further examined in various tissues, plasma and urine by means of HPLC, confirming complete loss of ergothioneine in all the tissue samples examined and plasma of octn1 −/− mice (Table I) .
Ergothioneine is a Substrate of Mouse OCTN1
When mouse OCTN1 or OCTN2 was heterologously transfected in HEK293 cells, only OCTN1, but not OCTN2 efficiently transports ergothioneine as a substrate ( Fig. 2A) , as previously reported for human and rat OCTN1 (3, 19) . The uptake of [ (Fig. 2B) , and reduced by the replacement of Na + in the medium (Fig. 2C ).
Intestinal Absorption, Distribution to Small Intestine and Renal Reabsorption of Ergothioneine
In general, ergothioneine is known as an extremely stable antioxidant which can directly scavenge reactive oxygen species, thereby protecting tissues against oxidative stress (20, 21) . Due to the minimal endogenous biosynthesis, the major source of ergothioneine for animals and plants is fungi and mycobacteria in soil (21) . Because quite limited information is available on details in biodistribution kinetics of ergothioneine in the body, we next examined the absorption and disposition of [ −/− mice, whereas that in wild-type mice was maintained for at least 2 weeks after oral administration (Fig. 3A) . This result was compatible with the much higher accumulation of [ 3 H] ergothioneine also in erythrocytes of wild-type mice (Fig. 3B) . The disappearance of [ mice, compared with wild-type mice (Fig. 3C) . Overshoot uptake of [ 3 H]ergothioneine was observed in renal brushborder membrane vesicles prepared from wild-type mice, but not in octn1 −/− mice (Supplementary Figure 3) . This suggests that ergothioneine is reabsorbed by OCTN1 in wild-type mice, but not in octn1 −/− mice, if we consider that OCTN1 is localized on brush-border membranes of proximal tubules (22) .
The tissue distribution of [ 3 H]ergothioneine after oral administration was then analyzed in both strains (Fig. 4) . The highest concentration of [ 3 H]ergothioneine was observed in upper and middle parts of small intestine at 4 hr after oral administration in wild-type mice (Fig. 4A) . However, such accumulation in small intestine cannot be observed in octn1 −/− mice (Fig. 4A) . The distribution of [ 3 H]ergothioneine to small intestine and other tissues was observed even at 14 days after oral administration in wild-type mice, but the distributed amount was much smaller in octn1 −/− mice (Fig. 4B) .
The octn1 −/− Mice Showed a Lower Tolerance to Intestinal Oxidative Stress Ergothioneine concentration in the small intestine was approximately 0.1 mM (∼20 μg/mL, Table I ). At such a concentration, ergothioneine behaves as a powerful chemical scavenger of a number of oxidizing species (23) . In addition, ergothioneine was found to be highly accumulated in small intestine (Fig. 4) , and exogenous administration of ergothioneine was reported to ameliorate oxidative stress in various tissues, including small intestine (24) . These data led us to examine whether or not octn1 −/− mice were more sensitive to small intestinal injury. For this purpose, ischemia and reperfusion were performed to generate a small-intestinal inflammatory model in mice (Fig. 5) . After the reperfusion, lethality was significantly higher in the octn1 −/− mice than in wild-type mice (Fig. 5A) . This was consistent with the more obvious loss of villus structures in small intestine of octn1 −/− mice (Fig. 5B) .
Decreased Blood Levels of Ergothioneine in CD Patients
The apparently greater susceptibility of octn1 −/− mice to intestinal inflammation (Fig. 5) further led us to examine a possible association of ergothioneine and inflammatory bowel disease in humans as well. As shown in the Table I , the blood samples in mice showed 16.5 μg/mL of ergothioheine, whereas the plasma ergothioneine concentration was much lower and close to the detection limit of HPLC, suggesting that the blood samples would be more useful for the comparison of the ergothioneine level between healthy volunteers and patients. Therefore, the ergothioneine concentration in blood of CD and UC patients was next examined by means of HPLC. As a result, CD patients exhibited much lower ergothioneine concentration in blood than healthy volunteers or patients with UC (Fig. 6) . Among the CD patients examined in the present study, no remarkable difference in the blood ergothioneine concentration was observed between patients with and without food restriction.
Genotyping of Patients with CD
To examine a direct linkage between CD and the OCTN1 gene in the patients examined in the present study, we sequenced all the exon regions of the OCTN1 and OCTN2 genes, determined the allelic frequency in CD patients for SNPs reported in the NCBI database, and then compared the results with those in healthy volunteers. The mutations reported to be associated with CD patients in Caucasians (C1672T/L503F in OCTN1 and G-207C in OCTN2) (8) were completely absent in Japanese CD patients examined in the present study (Supplementary Table III) . Furthermore, no other allelic frequencies exhibited a clear difference between CD patients and healthy volunteers (Supplementary Table III) .
DISCUSSION
In the present study, octn1 −/− mice were constructed to identify the in vivo substrates of OCTN1 with an aim to understand physiological roles of this transporter. Ergothioneine was identified as a physiological substrate of OCTN1 in the metabolome analysis (Fig. 1) . Ergothioneine was previously identified as a substrate of OCTN1 in gene transfectant systems in vitro (3) and, therefore, was examined similarly to over 100 other compounds in the metabolome analysis. Ergothioneine has a potent antioxidant property, and the source of ergothioneine in human and animals is solely food intake due to the minimal biosynthesis (20, 21) . Although the mice were given normal diets without any modification in the present study, ergothioneine was detected in their tissues. It would be possible that the normal diets contained a considerable amount of ergothioneine because of food chain resultant and/or contamination. The highest accumulation of ergothioneine in small intestine after oral administration (Fig. 4) implies that ergothioneine may protect against oxidative stress in this tissue. The slightly, but significantly, lower tolerance to intestinal oxidative stress in octn1 −/− mice (Fig. 5) supports such anti-oxidant activity exerted by ergothioneine and further led us to examine the linkage between ergothioneine and CD patients (Fig. 6) . The diagnosis of CD is empirically based on endoscopic, radiologic and histological criteria (25) . On the other hand, the present finding proposes ergothioneine as a quantitative diagnostic marker to distinguish CD from healthy subjects and UC (Fig. 6) . It may be noteworthy that ergothioneine level in blood of UC patients is not so far away from that in healthy volunteers (Fig. 6 ), indicating specificity of the blood ergothioneine level between the two inflammatory bowel diseases. To our knowledge, there has been no report indicating such quantitative markers which are closely relevant to CD and can be easily determined in patients. Thus, combination of gene knockout and metabolome analysis has finally revealed the basis for a diagnostic tool to distinguish CD from UC and healthy condition.
The present study has also proposed a close interrelationship between OCTN1 and ergothioneine. Ergothioneine has a unique feature in its pharmacokinetics: Plasma and blood concentration of ergothioneine is maintained for at least 14 days in wild-type mice after a single oral administration (Fig. 3A and B) . This is probably because of large tissue distribution, tissue-to-plasma concentration ratio being more than 10 in small intestines, liver and kidney (Fig. 4A ), but small urinary excretion of ergothioneine, the amount excreted for 14 days after oral administration, being at most 10% of dose in wild-type mice (Fig. 3C) . On the other hand, the plasma and blood concentration of ergothioneine transiently increased and then gradually decreased in octn1 −/− mice after oral administration ( Fig. 3A and B) due to much lower tissue distribution (Fig. 4) and much higher urinary excretion (Fig. 3C) . The transient increase in plasma and blood concentration of ergothioneine in octn1 −/− mice, which appeared to be absent in wild-type mice (Fig. 3A and 3B ), could be explained by the remarkable difference in the distribution of ergothioneine to the liver (Fig. 4A) : The Kp value in the liver exhibited approximately 200 times difference between wild-type and octn1 −/− mice (Fig. 4A ). This may support the hypothesis that the liver plays a first-pass elimination organ in wild-type mice, but not in octn1 −/− mice, although this hypothesis should be verified by further analyses. The higher urinary excretion of ergothioneine in octn1 −/− mice would be due to reabsorption of ergothioneine by OCTN1 if we consider that OCTN1 is localized on brush-border membranes of proximal tubules (22) , can transport ergothioneine (Fig. 2) and is involved in influx of ergothioneine in renal brush-border membrane vesicles (Supplemental Figure 3) . Both ergothioneine level (Table I) (Fig. 4) were almost completely reduced in octn1 −/− mice, and this was compatible with ubiquitous expression of OCTN1 in all the tissues examined (1). Thus, OCTN1 is involved in both tissue distribution and renal reabsorption of ergothioneine, thereby contributing to maintain steady-state ergothioneine level in the body.
It may be noteworthy that the wild-type mice showed distinct kinetics in the ergothioneine concentration between the plasma and blood: Ergothioneine level in blood increased slowly and reached the plateau at 6 days, whereas plasma ergothioneine level was high at 1-3 days (Fig. 3A and B) . It was suggested that OCTN1 is highly expressed in glycophorin A-positive erythroid cells and possibly associated with erythroid-lineage cells at the transition stage from immature erythroid cells to peripheral mature erythrocytes (26) . Combined with the present results, it can be speculated that ergothioneine is taken up to the hematopoietic cells during their differentiation stage. The slow increase in the ergothioneine level in the blood (Fig. 3B) In addition to the close interrelationship with OCTN1, ergothioneine seems to be relevant to a certain intestinal inflammatory status. This hypothesis was supported by the lower ergothioneine level in CD patients than healthy volunteers (Fig. 6 ) and slightly lower tolerance to intestinal oxidative stress in octn1 −/− mice (Fig. 5) , in which ergothioneine level was under the detection limit (Table I) . Exogenous administration of ergothioneine was reported to ameliorate oxidative stress in various tissues, including small intestine (24) . Therefore, the effect of ergothioneine treatment on clinical symptoms of CD patients needs to be examined to clarify whether ergothioneine has a potential ameliorating effect on the intestinal inflammation. The pharmacokinetic analysis in the present study indicated that ergothioneine is orally absorbed even in octn1 −/− mice ( Fig. 3A and B) , suggesting that ergothioneine exogenously administered could be exposed inside the small intestinal epithelium even when OCTN1 is functionally defective. While ergothioneine is generally thought to work as antioxidant in the body, its actual function in vivo has been questioned, indicating the possibility that ergothioneine has an other unknown function directly related to CD. However, identification of the biological activities of ergothioneine has been hindered by the absence of experimental animals deficient in ergothioneine. Because the present study has revealed minimal presence of ergothioneine in octn1 −/− mice, but much higher concentration (μM or mM level) of ergothioneine in wild-type mice (Table I) , this octn1 −/− mice may be a suitable tool to demonstrate diverse activities of ergothioneine in vivo.
In the present study, the contribution of other transporter(s) to the membrane permeation of ergothioneine was also implied. For example, ergothioneine was substantially taken up by the mock cells without transfection of OCTN1 gene (Fig. 2B) , and octn1 −/− mice showed a transient increase in the plasma and blood level of ergothioneine after oral administration ( Fig. 3A and B) . In addition, significant difference was observed in ergothioneine level between CD patients and other groups (Fig. 6 ), but the difference was not so obvious, compared with that observed between wild-type and octn1 −/− mice (Table I ). Therefore, it is possible that transporter(s) other than OCTN1 may contribute to ergothioneine transport in the body. Further studies will be needed for its molecular identification.
Gene knockout mice have been widely applied to analyze the roles of transporters but often exhibit minimal phenotype possibly due to the compensation by other transporter gene products in vivo and/or functional redundancy provoked by homologous transporters with overlapped substrate specificity (27, 28) . This may also be true for OCTN1, if we consider minimal phenotype found in octn1 −/− mice at least in normal breeding condition (see "Results"). Thus, application of the metabolomics approach would be a powerful tool to identify any phenotypic difference between wild-type and knockout mice. Metabolome analysis has been recently established to simultaneously measure whole metabolite profiles in the body, and application of this technology to whole organs of the gene knockout animals may identify physiologically important substrates, providing a clue to understand any physiological relevance of the transporters.
The possible association between CD and OCTN1 was not fully demonstrated in the present study. Association between OCTN1 gene and CD had been controversial, and this could be compatible with the present finding that the mutations reported to be associated with CD patients in Caucasians were completely absent in Japanese CD patients ( Supplementary Table III) and that no allelic frequencies exhibited a clear difference between CD patients and healthy volunteers (Supplementary Table III) . However, steady-state ergothioneine level appears to be governed by OCTN1 according to the present findings (Table I ). In addition, since ergothioneine is minimally biosynthesized or metabolized in animals (20, 21, 29, 30 ), transporter(s) involved in its absorption and disposition would be likely to regulate the steadystate level of ergothioneine. Therefore, it is necessary to directly examine the function of OCTN1 in CD patients to clarify the possible relation between the lower ergothioneine level in CD patients (Fig. 6 ) and OCTN1 activity in those patients.
In conclusion, the combination of two biotechnological tools, gene knockout and metabolome analysis, has revealed a pivotal role of OCTN1 in ergothioneine homeostasis, which could be related to intestinal inflammations, providing the basis for a diagnostic tool for CD in humans.
